Skip to main content

Advertisement

SpringerLink
Log in

Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Rates of adherence and persistence with endocrine therapy regimens (i.e., tamoxifen, aromatase inhibitors) by breast cancer survivors are suboptimal, with negative implications for prognosis. This study identified potential contributors to nonadherence and nonpersistence. From an online breast cancer research registry (Army of Women) including approximately 51,000 breast cancer survivors, we recruited 1,371 women who currently were taking endocrine therapy and 94 nonpersisters (i.e., diagnosed during the prior 5 years and on endocrine therapy within the prior 12 months, but no longer taking it). Participants completed an online questionnaire assessing demographic/medical characteristics, general and cancer-related psychosocial variables (i.e., depressive symptoms, anxiety, patient–oncologist relationship quality, cancer recurrence worry, general symptoms), and endocrine therapy-specific variables (i.e., endocrine therapy-related symptoms, perceived endocrine therapy necessity, long-term therapy use concern, endocrine therapy-related emotions). Two weeks later, current users were re-contacted to complete an endocrine therapy adherence measure. In a final regression model, patient-reported nonadherence among current users was significantly associated with lower financial status, a prior switch in endocrine therapies, a poorer relationship with the oncologist, and lower perceived need for and more negative emotions regarding endocrine therapy (adjusted R 2 = 0.15, P < 0.001). In a final logistic regression model, endocrine therapy nonpersisters were significantly more likely than current users to report depressive symptoms, as well as more negative emotions and lower positive emotions related to endocrine therapy (adjusted R 2 = 0.10, P < 0.001). In addition to demographic/medical variables, several potentially modifiable psychosocial characteristics are likely to contribute to endocrine therapy nonadherence and nonpersistence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784–3796

    Article  PubMed  Google Scholar 

  2. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134:459–478

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99:1763–1768

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108:1515–1524

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Hershman DL, Shao T, Kushi LH et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529–537

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G (2013) Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival in low income women. Am J Clin Oncol 36:181–187

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Haynes RB, Sackett DL (1979) Compliance in health care. Johns Hopkins University Press, Baltimore, MD

    Google Scholar 

  8. Liu Y, Malin JL, Diamant AL, Thind A, Maly RC (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat 137:829–836

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment: a meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160:2101–2107

    Article  CAS  PubMed  Google Scholar 

  10. Grenard JL, Munjas BA, Adams JL, Suttorp M, Maglione M, McGlynn EA, Gellad WF (2011) Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis. J Gen Intern Med 26:1175–1182

    Article  PubMed Central  PubMed  Google Scholar 

  11. Gonzalez JS, Batchelder AW, Psaros C, Safren SA (2011) Depression and HIV/AIDS treatment adherence: a review and meta-analysis. J Acquir Immun Defic Syndr 58:181–187

    Google Scholar 

  12. Hay JL, McCaul KD, Magnan RE (2006) Does worry about breast cancer predict screening behaviors? A meta-analysis of the prospective evidence. Prev Med 42:401–408

    Article  PubMed  Google Scholar 

  13. Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19:322–328

    CAS  PubMed  Google Scholar 

  14. Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Counsel 59:97–102

    Article  Google Scholar 

  15. Lash TL, Fox MP, Westrup LJ, Fink AK, Silliman RA (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215–220

    Article  PubMed  Google Scholar 

  16. Owusu C, Buist DS, Field TS et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26:549–555

    Article  PubMed  Google Scholar 

  17. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22:3309–3315

    Article  PubMed  Google Scholar 

  18. Ziller V, Kalder M, Albert U-S, Holzhauer W, Ziller M, Wagner U, Hadji P (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Annals Oncol 20:431–436

    Article  CAS  Google Scholar 

  19. Horne R, Weinman J (1999) Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 47:555–567

    Article  CAS  PubMed  Google Scholar 

  20. Gierisch JM, Earp JA, Brewer NT, Rimer BK (2010) Longitudinal predictors of nonadherence to maintenance of mammography. Cancer Epidemiol Biomarkers Prev 19:1103–1111

    Article  PubMed Central  PubMed  Google Scholar 

  21. Zigmond AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361–370

    Article  CAS  PubMed  Google Scholar 

  22. Vodermaier A, Linden W, Siu C (2009) Screening for emotional distress in cancer patients: a systematic review of assessment instruments. J Natl Cancer Inst 101:1464–1488

    Article  PubMed Central  PubMed  Google Scholar 

  23. Tracey TJ, Kokotovic AM (1989) Factor structure of the working alliance inventory. Psychol Assess 1:207–210

    Article  Google Scholar 

  24. Busseri MA, Tyler JD (2003) Interchangeability of the working alliance inventory and working alliance inventory, short form. Psychol Assess 15:193–197

    Article  PubMed  Google Scholar 

  25. Horvath AO, Greenberg LS (1989) Development and validation of the working alliance inventory. J Counseling Psychol 36:223–233

    Article  Google Scholar 

  26. Stanton AL, Bernaards CA, Ganz PA (2005) The BCPT Symptom Scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer. J Natl Cancer Inst 97:448–456

    Article  PubMed  Google Scholar 

  27. Zivian MT, Salgado B (2008) Side effects revisited: women’s experiences with aromatase inhibitors. Breast Cancer Action. http://archive.bcaction.org/uploads/PDF/AIReport.pdf

  28. Crites SL, Fabrigar LR, Petty RE (1994) Measuring the affective and cognitive properties of attitudes: conceptual and methodological issues. Pers Soc Psychol Bull 20:619–634

    Article  Google Scholar 

  29. Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67–74

    Article  CAS  PubMed  Google Scholar 

  30. Lavsa SM, Holzworth A, Ansani NT (2011) Selection of a validated scale for measuring medication adherence. J Am Pharm Assoc 51:90–94

    Article  Google Scholar 

  31. Horne R, Weinman J (2002) Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health 17:17–32

    Article  Google Scholar 

  32. ATAC Trialists’ Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62

    Article  Google Scholar 

  33. Lin JH, Zhang SM, Manson JE (2011) Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res 4:1360–1365

    Article  CAS  Google Scholar 

  34. Sedjo RL, Devine S (2011) Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 125:191–200

    Article  CAS  PubMed  Google Scholar 

  35. Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H, Bergkvist L, Lambe M (2012) Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat 133:367–373

    Article  CAS  PubMed  Google Scholar 

  36. Hart SL, Hoyt MA, Diefenbach M, Anderson DR, Kilbourn KM, Craft LL, Steel JL, Cuijpers P, Mohr DC, Berendsen M, Spring B, Stanton AL (2012) Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. J Natl Cancer Inst 104:990–1004

    Article  PubMed Central  PubMed  Google Scholar 

  37. Schneider S, Moyer A, Knapp-Oliver S, Sohl S, Cannella D, Targhetta V (2010) Pre-intervention distress moderates the efficacy of psychosocial treatment for cancer patients: a meta-analysis. J Behav Med 33:1–14

    Article  PubMed Central  PubMed  Google Scholar 

  38. Haskard-Zolnierek KB, DiMatteo MR (2009) Physician communication and patient adherence to treatment: a meta-analysis. Med Care 47:826–834

    Article  PubMed Central  Google Scholar 

  39. McCorkle R, Ercolano E, Lazenby M, Schulman-Green D, Schilling LS, Lorig K, Wagner EH (2011) Self-management: enabling and empowering patients living with cancer as a chronic illness. CA Cancer J Clin 61:50–62

    Article  PubMed Central  PubMed  Google Scholar 

  40. Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 15:602–606

    Article  Google Scholar 

  41. Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB (2004) The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care 42:649–652

    Article  PubMed  Google Scholar 

  42. Waterhouse DM, Calzone KA, Mele C, Brenner DE (1993) Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11:1189–1197

    CAS  PubMed  Google Scholar 

  43. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA (2006) Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav 10:227–245

    Article  PubMed  Google Scholar 

  44. Phillips KA, Milne RL, Buys S, Friedlander ML, Ward JH, McCredie MR, Giles GG, Hopper JL (2005) Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry. J Clin Oncol 23:4679–4686

    Article  PubMed  Google Scholar 

  45. Bjorner JB, Rose M, Gandek B, Stone AA, Junghaenel DU, Ware JE (2014) Method of administration of PROMIS scales did not significantly impact score level, reliability, or validity. J Clin Epidemiol 67:108–113

    Article  PubMed  Google Scholar 

  46. DiMatteo MR (2004) Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol 23:207–218

    Article  PubMed  Google Scholar 

  47. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev, Issue 2. Art. No.: CD000011. doi:10.1002/14651858.CD000011.pub3

  48. Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B (1998) Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care 36:1138–1161

    Article  CAS  PubMed  Google Scholar 

  49. Hadji P, Blettner M, Harbeck N, Jackisch C, Lück HJ, Windemuth-Kieselbach C, Zaun S, Kreienberg R (2013) The Patient’s Anastrozole Compliance to Therapy (PACT) program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol 24:1505–1512

    Article  CAS  PubMed  Google Scholar 

  50. Ziller V, Kyvernitakis I, Knöll D, Storch A, Hars O, Hadji P (2013) Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment—the COMPAS study. BMC Cancer 13:407. doi:10.1186/1471-2407-13-407

    Article  PubMed Central  PubMed  Google Scholar 

  51. Duijts SF, van Beurden M, Oldenburg HS et al (2012) Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol 30:4124–4133

    Article  PubMed  Google Scholar 

  52. Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59:56–66

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This research was supported by funding from the Breast Cancer Research Foundation (Stanton).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Departments of Psychology and Psychiatry/Biobehavioral Sciences, Center for Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, 1285 Franz Hall, Box 90095-1563, Los Angeles, CA, USA

    Annette L. Stanton

  2. Department of Psychological Medicine, University of Auckland, Auckland, New Zealand

    Keith J. Petrie

  3. Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Ann H. Partridge

Authors
  1. Annette L. Stanton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keith J. Petrie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ann H. Partridge
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Annette L. Stanton.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stanton, A.L., Petrie, K.J. & Partridge, A.H. Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat 145, 525–534 (2014). https://doi.org/10.1007/s10549-014-2961-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-014-2961-3

Keywords

Search

Navigation